Maintenance fees coming due
8 maintenance fees come due in the 12 months from Nov 16, 2026, the next on Apr 30, 2027. Unpaid by Nov 1, 2027, that one lapses early.
A maintenance fee does not end a patent on its due date. It falls due at 3.5, 7.5
and 11.5 years from grant, and the patent lapses only if the fee is still unpaid at the end of the
six month grace period that follows.
| Patent | Title | Holder | Status | Fee due | Lapses if unpaid | Expires | Confidence |
|---|---|---|---|---|---|---|---|
| US 11,801,300 | Pharmaceutical Products and Stable Liquid Compositions of IL-17 Antibodies In force Fee due Apr 30, 2027 Lapses if unpaid Nov 1, 2027 · High confidence | Novartis Pharma AG | In force | Apr 30, 2027 | Nov 1, 2027 | High confidence | |
| US 11,807,855 | Selection Vectors and Methods of Selecting Eukaryotic Host Cells In force Fee due May 7, 2027 Lapses if unpaid Nov 8, 2027 · High confidence | Novartis Pharma AG | In force | May 7, 2027 | Nov 8, 2027 | High confidence | |
| US 10,501,525 | Methods for Purification of Antibodies Using Aliphatic Alcohols In force Fee due Jun 10, 2027 Lapses if unpaid Dec 10, 2027 · High confidence | Novartis Pharma AG | In force | Jun 10, 2027 | Dec 10, 2027 | High confidence | |
| US 11,851,666 | Multi-Copy Gene Protein Expression System In force Fee due Jun 26, 2027 Lapses if unpaid Dec 27, 2027 · High confidence | Novartis Pharma AG | In force | Jun 26, 2027 | Dec 27, 2027 | High confidence | |
| US 9,220,631 | Syringe In force Fee due Jun 29, 2027 Lapses if unpaid Dec 29, 2027 · High confidence | Novartis Technology LLC, Novartis Pharmaceuticals Corporation and Novartis Pharma AG | In force | Jun 29, 2027 | Dec 29, 2027 | High confidence | |
| US 11,865,109 | Formulations of (S)-3-Amino-6-Methoxy-N-(3,3,3-Trifluoro-2-Hydroxy-2-Methylpropyl)-5-(TRIFLUOROMETHYL)PICOLINAMIDE In force Fee due Jul 9, 2027 Lapses if unpaid Jan 10, 2028 · High confidence | Novartis AG | In force | Jul 9, 2027 | Jan 10, 2028 | High confidence | |
| US 10,583,190 | Methods of Treating Psoriasis Using IL-17 Antibodies In force Fee due Sep 10, 2027 Lapses if unpaid Mar 10, 2028 · Medium confidence | Novartis Pharma AG | In force | Sep 10, 2027 | Mar 10, 2028 | Medium confidence | |
| US 9,295,668 | Use of an Aromatase Inhibitor for the Treatment of Hypogonadism and Related Diseases In force Fee due Sep 29, 2027 Lapses if unpaid Mar 29, 2028 · High confidence | Mereo Biopharma 2 Limited | In force | Sep 29, 2027 | Mar 29, 2028 | High confidence |
8 of 8 patents shown. Soonest fee due date first, then patent number.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.